FDA Approves Cobenfy
The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), making it the first major advancement in schizophrenia treatment in decades.
Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The ...
The first new kind of treatment for schizophrenia patients in decades is arriving. The U.S. Food and Drug Administration approved the drug on Thursday, greenlighting the first of a new class of ...
Formally known as KarXT, xanomeline-trospium chloride (Cobenfy) receives approval from the FDA for the treatment of schizophrenia in adults. The FDA approved xanomeline and trospium chloride ...
At half the cost of most private facilities and treatment centers, the Utah Addiction Centers' multi-disorder treatment provides personalized outpatient and residential treatment for depression ...
A new drug has been approved for the treatment of schizophrenia in adults. On Thursday, the U.S. Food and Drug Administration (FDA) approved COBENFY (xanomeline and trospium chloride), an oral ...
About one in 300 people worldwide are affected by schizophrenia, but for decades treatment options have been both static and limited. If the FDA approves the twice-daily pill on Thursday ...